Niagen Bioscience expands Tru Niagen retail footprint with GNC and Sam's Club. At GNC, shoppers can find Tru Niagen Beauty, a supplement designed to support skin elasticity and the appearance of hair, skin and nails. August 26, 2026 Associate Editor, Happi Tru Niagen, a leader in healthy-aging NAD-boosting supplement in the US, has expanded its retail footprint at GNC and Sam's Club. "Expanding Tru Niagen across GNC and Sam's Club strengthens our retail footprint and puts the category-leading NAD+ supplement in front of new consumer audiences," said Rob Fried, CEO of parent company Niagen Bioscience. "These partnerships reflect the growing demand for credible, science-backed healthy aging solutions." With the latest retail expansion, Tru Niagen is available in nearly 300 retail locations across 44 states combined. At GNC, shoppers can find Tru Niagen Beauty, a supplement in the US featuring Niagen (patented nicotinamide riboside or NR) designed to support skin elasticity and the appearance of hair, skin and nails, along with Tru Niagen 300-mg 30-count bottles in store and online. Sam's Club shoppers can purchase Tru Niagen 300mg 120-count bottles in store and online. Supporting cellular function and healthy aging, Tru Niagen is clinically shown to increase NAD+ levels and help sustain them over time. It's powered by Niagen (patented nicotinamide riboside, or NR), a high-quality NAD-booster. NAD+ is an essential coenzyme vital to cellular health, mitochondrial function, cellular energy production and DNA repair. Embodying high scientific and quality standards, Tru Niagen is reportedly backed by more than 45 human clinical studies, over 500 published scientific studies and more than 60 patents worldwide.

Niagen Bioscience to present at the 17th annual Midwest IDEAS Investor Conference. LOS ANGELES-(BUSINESS WIRE)-$NAGE #Biotech - Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the Midwest IDEAS Investor Conference on Thursday, August 27, 2026, at The InterContinental Chicago in Chicago, IL. IDEAS Conferences offer independent regional venues for top-tier companies to present their investment merits to instrumental audiences of investment professionals, offering investor-sponsored events created to benefit regional investment communities. Niagen Bioscience CFO, Ozan Pamir, will present on Thursday, August 27, from 2:40 - 3:15 PM CT in Presenting Room 2 and be available for one-on-one meetings with institutional investors at the conference. The presentation will be livestreamed and can be accessed through the conference host's main website: www.threepartadvisors.com/midwest. If you would like to schedule a one-on-one meeting with the Niagen Bioscience management team during the conference, please contact your respective conference representative or email [email protected]. About Niagen Bioscience Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience(TM) is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen(R)(patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen(R), the number one NAD+ boosting oral supplement in the United States (available at www.truniagen.com), and Niagen(TM) Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company's wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated molecule. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published. Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 - Dec. 2025) Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310.405.5227 [email protected] Niagen Bioscience Investor Relations Contact: Valter Pinto, Managing Director KCSA Strategic Communications 212.896.1254 [email protected] August 13th, 2026 August 12th, 2026

Niagen Bioscience: Q2 earnings snapshot. August 4, 2026, 4:35 PM LOS ANGELES (AP) - LOS ANGELES (AP) - Niagen Bioscience, Inc. (NAGE) on Tuesday reported profit of $963,000 in its second quarter. On a per-share basis, the Los Angeles-based company said it had profit of 1 cent. The natural products company posted revenue of $29.8 million in the period. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NAGE at https://www.zacks.com/ap/NAGE Keep Watching 1 dead, 7 injured after two-vehicle crash in Germantown